Friday, May 15, 2026

Clinical Trial News 15-May-2026

FDA Drug Approvals

Veppanu (vepdegestrant): Approved 01-May-2026 for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following endocrine therapy. Developed by Arvinas.

Bizengri (zenocutuzumab-zbco): Approved 08-May-2026 for advanced or metastatic cholangiocarcinoma with NRG1 gene fusion after prior systemic therapy. Partner Therapeutics.

Beqalzi (sonrotoclax): Accelerated approval granted 13-May-2026 for relapsed or refractory mantle cell lymphoma after at least two prior therapies including a BTK inhibitor. BeOne Medicines.

Inqovi + Venetoclax Combination: Approved 13-May-2026 for newly diagnosed acute myeloid leukemia in older adults or those unable to undergo intensive induction chemotherapy. Taiho Oncology.

FDA Real-Time Clinical Trials Pilot: FDA launched a new initiative enabling regulators to monitor aggregated clinical trial data in near real time, aiming to reduce development timelines and administrative delays.

M&A Deals

Isomorphic Labs Funding Round: AI drug discovery company Isomorphic Labs raised $2.1 billion to scale AI-powered drug design platforms and accelerate movement toward first human trials. Backed by Alphabet, GV, and Thrive Capital.

Biopharma M&A Surge Continues: Q1 2026 biotech deal value reached approximately $84 billion, nearly double the same period last year, driven by looming patent expirations and pipeline gaps across major pharma companies.

Generate Biomedicines IPO Push: Generate Biomedicines filed for a U.S. IPO targeting a valuation of roughly $2.2 billion, highlighting investor appetite for AI-native biotech firms.

Clinical Trial Setbacks

Replimune RP1 Rejection: FDA again rejected Replimune’s melanoma therapy RP1 after determining the company failed to sufficiently address concerns related to clinical trial data and study interpretation.

Regenxbio RGX-121 CRL Fallout: Regenxbio received an FDA rejection for its Hunter syndrome gene therapy RGX-121, citing concerns over trial design, endpoints, and use of natural history controls.

Regulatory Uncertainty at FDA: The unexpected resignation of FDA Commissioner Marty Makary introduced concerns around regulatory consistency, leadership stability, and review timelines across biotech.

Technological Breakthroughs

FDA Real-Time Clinical Trials Initiative: The FDA’s new pilot program allows continuous review of aggregated clinical trial data rather than waiting for traditional milestone submissions. Companies including Johnson & Johnson, AstraZeneca, and Amgen are participating.

AI-Powered IND Acceleration: Sponsors increasingly report dramatic reductions in regulatory document preparation time through generative AI systems. FDA and industry leaders are moving toward AI-assisted submission review and automated signal detection.

Bayesian Trial Designs Gain Momentum: FDA’s 2026 draft guidance on Bayesian methodologies is pushing broader adoption of adaptive and platform trial models, especially in rare disease and oncology development.

Market Insights

Patent Cliff Pressure Intensifies: Analysts estimate more than $300 billion in branded drug revenue is vulnerable to loss of exclusivity over the next five years, fueling aggressive acquisition activity across oncology, immunology, obesity, and rare disease biotech.

AI Biotech Still Faces Skepticism: While investment into AI drug discovery continues exploding, many researchers and biotech professionals remain cautious about claims that AI alone can improve clinical success rates without stronger biological datasets and wet lab validation.

Regulatory Modernization Accelerates: FDA’s broader modernization push now includes AI integration, faster inspections, real-time trial oversight, and expanded use of adaptive evidence generation models.

Summary: Major FDA Actions — May 2026

Brand NameActive IngredientCompanyIndicationApproval Date
VeppanuVepdegestrantArvinasER+/HER2- Metastatic Breast Cancer01-May-2026
BizengriZenocutuzumab-zbcoPartner TherapeuticsNRG1+ Cholangiocarcinoma08-May-2026
BeqalziSonrotoclaxBeOne MedicinesRelapsed/Refractory Mantle Cell Lymphoma13-May-2026
Inqovi + VenetoclaxDecitabine/Cedazuridine + VenetoclaxTaiho OncologyNewly Diagnosed AML13-May-2026

Quick Links

- No comments:
Labels: , , ,

Tuesday, April 14, 2026

Clinical Trial News 14-Apr-2026

 

Clinical Trials Monthly: April 2026

FDA Approvals

The U.S. Food and Drug Administration (FDA) remained active in April, with several notable approvals and label expansions.

  • Alzheimer’s therapy expansion: The FDA expanded labeling for an anti-amyloid therapy to include earlier-stage patients, continuing its cautious support of this drug class.
  • Rare disease gene therapy: A one-time gene therapy for a pediatric neuromuscular disorder received approval, reflecting continued momentum in high-impact rare disease treatments.

Sources:
https://www.fda.gov/news-events/press-announcements
https://www.fda.gov/drugs/news-events-human-drugs

M&A Deals

Biotech dealmaking showed signs of recovery, with a focus on strategic and lower-risk structures.

  • Oncology acquisition: A large pharmaceutical company acquired a clinical-stage oncology biotech in a multi-billion dollar deal centered on a Phase II asset.
  • AI-driven partnerships: Companies increasingly pursued partnerships with milestone-based structures rather than full acquisitions.

Sources:
https://www.reuters.com/markets/deals/
https://www.bloomberg.com/markets

Clinical Trial Successes & Setbacks

Successes

  • Obesity and metabolic disease: A Phase III GLP-1 combination therapy demonstrated significant weight loss and metabolic improvements.
  • Oncology: A targeted therapy met its primary endpoint, improving progression-free survival in a biomarker-defined population.

Setbacks

  • Alzheimer’s disease: A late-stage trial targeting a novel pathway failed to meet endpoints, highlighting ongoing challenges in CNS drug development.
  • Immunology safety concerns: A trial was partially placed on hold due to adverse events.

Sources:
https://www.nejm.org/
https://www.thelancet.com/
https://www.statnews.com/
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts

Tech Breakthroughs

  • Decentralized trials: Hybrid trial models continue to expand, improving patient access and enrollment timelines.
  • Digital endpoints: Wearables and digital biomarkers are gaining regulatory acceptance for use in clinical trials.

Sources:
https://www.mckinsey.com/industries/life-sciences
https://www.nature.com/

AI Developments

  • Protocol optimization: AI tools are being used to simulate trial designs and reduce amendments.
  • Patient recruitment: Machine learning models are improving patient matching and site selection.
  • Regulatory engagement: The FDA continues to explore frameworks for AI use in drug development.

Sources:
https://www.technologyreview.com/
https://www.deloitte.com/
https://www.fda.gov/science-research/artificial-intelligence

Market Insights

  • Funding: Biotech venture funding showed modest recovery following prior downturns.
  • IPO activity: The IPO market reopened cautiously, with stable but not high-performing entries.
  • Pipeline focus: Continued investment in obesity, oncology, and CNS therapies.

Sources:
https://www.wsj.com/finance
https://www.reuters.com/markets

Summary

  • FDA continues active approvals with increased scrutiny
  • M&A activity returning with more disciplined deal structures
  • Strong performance in metabolic disease; continued challenges in Alzheimer’s
  • Incremental progress in decentralized trials and digital endpoints
  • AI adoption expanding in trial design and execution
  • Market conditions stabilizing with cautious optimism
- No comments:

Friday, March 13, 2026

Clinical Trial News: 13-Mar-2026

Here's your full roundup of what's been moving in clinical trials, FDA decisions, M&A, and policy.

FDA Drug Approvals

Keytruda / Keytruda Qlex (pembrolizumab) — Ovarian Cancer: The biggest oncology approval of the period. The FDA approved Keytruda and Keytruda Qlex in combination with paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who have received one or two prior treatment regimens. Based on the Phase 3 KEYNOTE-B96 trial, the regimen reduced the risk of disease progression or death by 28% and the risk of death by 24% vs. placebo. This is the first PD-1 inhibitor ever approved for this population — a population that historically had almost nothing after platinum failure. A big moment for the field. FDA Link | Merck Press Release

Adquey (difamilast 1% ointment): Approved February 12, 2026 for mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 and older. A novel non-steroidal topical PDE4 inhibitor from Acrotech Biopharma and Otsuka — the third PDE4 inhibitor in this class, joining crisaborole and roflumilast. No application-site stinging issue that plagued earlier entrants, and a strong Phase III IGA success rate. FDA Approval Letter | Acrotech Press Release

Filkri (filgrastim-laha): Approved February 17, 2026 as a biosimilar to Neupogen for neutropenia across multiple oncology and radiation settings. Accord BioPharma's sixth biosimilar approval — part of a stated push to build one of the deepest biosimilar portfolios in the industry. More competition, more access, lower costs. The biosimilar engine keeps running. Accord BioPharma Press Release

Bysanti (milsaperidone): Approved February 20, 2026 for acute bipolar I disorder and schizophrenia in adults. Vanda Pharmaceuticals' new chemical entity that rapidly interconverts to iloperidone — a pharmacokinetic bridging strategy that allowed the FDA review to leverage 100,000+ patient-years of iloperidone real-world data. Commercial availability expected Q3 2026, with a Phase 3 MDD adjunctive study reading out by year-end. Vanda Press Release

Loargys (pegzilarginase-nbln): FDA granted accelerated approval February 23, 2026 to Immedica Pharma's enzyme replacement therapy for hyperargininemia in patients aged 2 and older with Arginase 1 Deficiency — an ultra-rare metabolic disorder affecting only an estimated 250 patients in the U.S. First and only therapy proven to lower plasma arginine. Expected to be commercially available in April 2026. FDA Approval Letter | Immedica Press Release

Desmoda (desmopressin acetate oral solution): Approved February 25, 2026 for central diabetes insipidus across all ages. A new formulation of a well-established molecule — important for patients who can't use intranasal or injectable routes. Source

Summary Table: Recent FDA Actions (Feb 12 – Mar 13, 2026)

Brand Name Active Ingredient Company Indication Approval Date
Keytruda / Keytruda Qlex Pembrolizumab Merck Platinum-Resistant Ovarian Cancer (PD-L1+) 10-Feb-2026
Adquey Difamilast 1% Acrotech / Otsuka Atopic Dermatitis 12-Feb-2026
Filkri Filgrastim-laha Accord BioPharma Neutropenia (Biosimilar to Neupogen) 17-Feb-2026
Bysanti Milsaperidone Vanda Schizophrenia / Bipolar I 20-Feb-2026
Loargys Pegzilarginase-nbln Immedica Arginase 1 Deficiency 23-Feb-2026
Desmoda Desmopressin acetate — Central Diabetes Insipidus 25-Feb-2026

M&A Deals

Servier acquires Day One Biopharmaceuticals: $2.5 billion (Announced March 6, 2026). An all-cash deal expected to close Q2 2026, adding Day One's pediatric low-grade glioma program to Servier's rare oncology portfolio. Servier is foundation-governed rather than shareholder-driven, which makes this a notably long-term bet rather than a near-term commercial play. Source

GSK licenses linerixibat to Alfasigma: up to $690 million (Announced March 9, 2026). GSK out-licenses its cholestatic pruritus drug for primary biliary cholangitis to Italian pharma Alfasigma — $300M upfront and $100M on approval, with a PDUFA date of March 24. It's always interesting when a company licenses away an asset days before a decision. Watch this one for context after the 24th. Source

Clinical Trial Setbacks

Claseprubart (CIDP) — Dianthus Therapeutics: Interim responder analysis results from the Phase 3 CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy came in on March 9, 2026. The data were mixed enough to keep investors on edge, though the company still has a full Phase 3 readout ahead and substantial cash runway into 2028. Source

North American Enrollment — A Brewing Regulatory Problem: Worth flagging as a trend: FDA's ODAC recently voted 8–1 against the applicability of the STARGLO trial's results to the US population, in large part because less than 5% of patients enrolled were from the United States. Regulators are increasingly scrutinizing multinational datasets that lack meaningful US representation. This isn't one failure — it's a pattern that could create late-stage approval risk for sponsors who rely heavily on ex-US enrollment. A conversation the industry needs to have now, not at submission. Source

Macro: The NIH Funding Disruption Is Real and Getting Bigger

This deserves its own section because it's affecting our world directly. A new analysis published in JAMA Internal Medicine found that NIH grant terminations have disrupted 383 clinical trials — about 1 in 30 of all active NIH-funded studies — affecting over 74,000 enrolled patients and representing $1.81 billion in lost funding. Infectious disease trials were hit hardest (14.4% terminated), followed by prevention-focused and behavioral intervention studies. The Northeast and globally-sited trials bore disproportionate impact. Source — AJMC

As one researcher put it: "Clinical trials aren't light switches. You can't just flip them off without consequences." The human cost is immediate; the scientific cost — missed evidence, disrupted longitudinal data, broken patient trust — compounds over years. Sponsors running trials with NIH co-funding or academic partnerships need to be actively pressure-testing their continuity plans right now.

Trials to Watch in the Coming Weeks

A few high-stakes readouts are imminent:

  • Orforglipron (Eli Lilly): March PDUFA date for this once-daily oral GLP-1. If approved, the pricing decision will set the tone for the entire oral obesity drug market. Oral GLP-1s are expected to capture roughly 20% of an $80B+ category by 2030 — how Lilly prices this one matters for everyone downstream. Source

  • Linerixibat (Alfasigma, formerly GSK): PDUFA March 24. First-in-class IBAT inhibitor for cholestatic pruritus in primary biliary cholangitis. The GSK-to-Alfasigma licensing deal announced March 9 added some intrigue to what was already a closely watched decision.

  • Pelacarsen (Novartis/Ionis): Phase 3 Lp(a)HORIZON data expected H1 2026. At least one analyst has called this the "biggest biotech event of the entire year" — if successful, it could establish Lp(a) as a mainstream cardiovascular treatment target and open up an entirely new drug class. Source

  • Remternetug (Eli Lilly, Alzheimer's): Top-line Phase 3 TRAILRUNNER-ALZ 1 data expected H1 2026. Lilly's next anti-amyloid antibody after donanemab — the Alzheimer's pipeline pressure is real and building.

The Big Picture

Three themes dominate this period.

The NIH funding situation is a structural risk, not a one-off. Sponsors, CROs, and sites that relied on federal co-funding need to redesign for resilience — politically-driven trial terminations mid-stream are now a real operational scenario, not a theoretical one.

Ovarian cancer finally has an immunotherapy option. The Keytruda approval in platinum-resistant disease closes a long-standing gap. The fact that this is the first positive IO trial in the space after years of failures is worth appreciating — it took the right trial design, the right population selection, and a companion diagnostic to make it work.

M&A remains aggressive and well-funded. The Servier and GSK deals this period are consistent with what the broader industry is projecting: 20+ acquisitions over $1B in 2026, driven by the patent cliff bearing down on most of the top 12 pharma companies. Rare oncology and CNS assets continue to command the highest premiums. Source

Quick Links

- No comments:

Thursday, March 12, 2026

The Biggest Clinical Trial Results of 2026 (So Far)

Clinical trials in early 2026 have already delivered some major moments—record-breaking obesity drug results, promising rare-disease therapies, and a few painful late-stage failures. Below are the trial results that are actually moving medicine, markets, and the future of drug development.

The obesity drug race just escalated again

The biggest headline so far this year comes from Eli Lilly, whose triple-agonist drug retatrutide produced unprecedented weight-loss results in a late-stage trial.

Patients lost nearly 29% of body weight after 68 weeks, pushing drug-induced weight loss closer to what we normally see with bariatric surgery. Earlier studies published in The New England Journal of Medicine already hinted at this level of efficacy, and the newer Phase 3 data confirms that multi-hormone drugs may become the next generation of obesity therapies.

Source
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

Why it matters: obesity drugs are now projected to become a $100B global market this decade, according to McKinsey & Company.
https://www.mckinsey.com/industries/life-sciences/our-insights/the-obesity-market-could-reach-100-billion-by-2030

Kidney disease may finally get a major new therapy

Another major result came from Vertex Pharmaceuticals, which reported strong Phase 3 data for povetacicept in IgA nephropathy.

The trial showed a 52% reduction in proteinuria, one of the key markers used to track disease progression. Patients also experienced large reductions in pathogenic antibodies associated with kidney damage.

Source
https://www.reuters.com/business/healthcare-pharmaceuticals/vertexs-kidney-disease-drug-meets-main-goal-late-stage-trial-2026-03-09/

Why it matters: IgA nephropathy affects hundreds of thousands globally, and treatment options are still limited.

Duchenne muscular dystrophy therapy shows promising functional benefit

In rare disease research, Capricor Therapeutics reported encouraging results for its cell therapy deramiocel in Duchenne muscular dystrophy.

Trial data showed an 83% slowing in decline of functional tasks, suggesting the therapy could significantly delay disease progression.

Source
https://www.stocktitan.net/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2025-zmo5hie061lg.html

An FDA decision is expected later in 2026.

Pulmonary fibrosis trial points to a new treatment approach

A pivotal trial evaluating inhaled treprostinil demonstrated improved lung function outcomes in idiopathic pulmonary fibrosis.

The study—reported in The New England Journal of Medicine—showed improved forced vital capacity and reduced disease progression compared with placebo.

Source
https://www.nejm.org

Why it matters: IPF is a devastating disease with limited therapeutic options.

A major breast-cancer trial disappointment

Not every big trial this year has succeeded.

A late-stage study of giredestrant, an oral estrogen-receptor degrader developed by Roche, failed to significantly improve progression-free survival in advanced breast cancer.

Source
https://www.wsj.com/health/pharma/roche-breast-cancer-treatment-falls-short-of-primary-goal-in-late-stage-study

The result is a setback for the oral SERD drug class, which had been expected to compete in a multibillion-dollar endocrine therapy market.

Quick snapshot of major trial readouts in 2026

TherapyCompanyDiseaseKey result
RetatrutideEli LillyObesity~29% weight loss
PovetaciceptVertexIgA nephropathy52% reduction in proteinuria
DeramiocelCapricorDuchenne muscular dystrophy83% slower functional decline
Treprostinil (inhaled)United TherapeuticsPulmonary fibrosisImproved lung function
GiredestrantRocheBreast cancerFailed Phase 3 endpoint

The big trends emerging in 2026 trials

Three patterns are becoming clear.

Obesity drugs are entering a new era.
Multi-hormone therapies are now delivering results once thought impossible with medication alone.

Rare diseases remain a major source of innovation.
Many of the most meaningful advances this year are coming from small patient populations.

The risk of drug development remains brutal.

Even promising drugs can fail in late-stage trials, wiping out years of work and billions in market value. 

- No comments:

Thursday, February 12, 2026

Clinical Trial News 12-Feb-2026

 FDA Drug Approvals

  • Darzalex Faspro (daratumumab and hyaluronidase-fihj): Label expansion approved 27-Jan-2026 in combination with VRd for newly diagnosed multiple myeloma patients ineligible for transplant. Johnson & Johnson. FDA Link

  • Zycubo (copper histidinate): Approved 12-Jan-2026 as the first treatment for Menkes disease, a rare copper metabolism disorder. FDA Link

  • Fibryga (fibrinogen, human): Expanded 2-gram kit approved 07-Jan-2026 for acquired fibrinogen deficiency, designed for faster administration in critical bleeding. Octapharma. FDA Link

  • Cablivi (caplacizumab-yhdp): Pediatric expansion approved 05-Jan-2026 for children 12 years with acquired thrombotic thrombocytopenic purpura (aTTP). Sanofi. FDA Link

  • Generic Glatiramer Acetate: Approved 05-Jan-2026 as the first complex injectable generic for relapsing multiple sclerosis. ScinoPharm. FDA Link

  • ProlivRx: Approved Jan 2026 as the first at-home, physician-directed neuromodulation device for Major Depressive Disorder (MDD).

M&A Deals

  • GSK acquires RAPT Therapeutics: $2.2 billion (Announced Jan 20, 2026). Secures RAPT’s oral small molecules for inflammation and oncology, strengthening GSK's respiratory/immunology pipeline. Source

  • AbbVie & RemeGen Licensing: $5.6 billion total (Jan 12, 2026). AbbVie gains rights to a bispecific antibody for oncology, continuing its aggressive expansion in targeted therapies. Source

  • Lilly & Seamless Therapeutics: $1.12 billion (Jan 28, 2026). A strategic collaboration focused on modular gene editing for neurological disorders. Source

  • AstraZeneca & SanegeneBio: $1.7 billion (Jan 30, 2026). Licensing deal for an RNAi technology platform to address metabolic and cardiovascular indications. Source

  • BMS & Janux Therapeutics: $1.035 billion (Jan 2026). Licensing deal for tumor-activated bispecific antibodies targeting solid tumors. Source

Clinical Trial Setbacks

  • Bausch Health (rifaximin SSD): Phase 3 Red-C trials failed (Jan 23, 2026). The Xifaxan successor did not meet primary objectives for the prevention of hepatic encephalopathy in cirrhosis patients. Source

  • Milvexian (J&J/BMS): Phase 3 futility analysis (Feb 2026) led to the early termination of the ACS (Acute Coronary Syndrome) study, though other Phase 3 indications remain active. Source

Technological Breakthroughs

  • NIH "Digital Twin" of the Eye: In Feb 2026, the NIH unveiled a high-resolution 3D digital replica of retinal pigment epithelial cells, providing a new AI-driven modeling platform to accelerate AMD drug discovery. Source

  • AI-Driven IND Streamlining: Data from Parexel in early 2026 shows AI systems are now preparing IND (Investigational New Drug) submissions 50% faster, significantly cutting the time from "ready" to "regulatory review." Source

Market Insights

  • The "Obesity Platform" Era: Experts at the 2026 J.P. Morgan Healthcare Conference noted a shift from mere GLP-1 novelty to supply chain scale and multi-modal platforms (oral, weekly, and combination therapies) to capture the projected $200B market. Source

  • Patent Cliff Pressure: 2026 marks the beginning of the "cliff," with over 40% of Big Pharma revenue at risk of loss of exclusivity (LoE) by 2030, driving the current 15% surge in late-stage M&A. Source

Summary Table: Recent Major FDA Actions

Brand Name

Active Ingredient

Company

Indication

Approval Date

Darzalex Faspro

Daratumumab

J&J

Newly Diagnosed Multiple Myeloma

27-Jan-2026

Zycubo

Copper histidinate

N/A

Menkes Disease

12-Jan-2026

Fibryga (2g)

Fibrinogen

Octapharma

Acquired Fibrinogen Deficiency

07-Jan-2026

Cablivi

Caplacizumab

Sanofi

Pediatric aTTP

05-Jan-2026

N/A (Generic)

Glatiramer Acetate

ScinoPharm

Relapsing Multiple Sclerosis

05-Jan-2026

ProlivRx

Neuromodulation

ProlivRx

MDD (At-Home Device)

Jan-2026

Quick Links

- No comments:

Monday, January 5, 2026

Clinical Trial News 05-Jan-2026

Clinical Trial News: Year-End 2025 Recap & January 2026 Kickoff

FDA Drug Approvals

  • Nereus (tradipitant): Approved 30-Dec-2025 for the prevention of vomiting associated with motion sickness in adults. Vanda Pharmaceuticals. FDA Link

  • Yartemlea (narsoplimab-wuug): Approved 24-Dec-2025 as the first treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Omeros Corporation. FDA Link

  • Aqvesme (mitapivat): Approved 23-Dec-2025 for the treatment of anemia in adults with alpha- or beta-thalassemia. Agios Pharmaceuticals. FDA Link

  • Myqorzo (aficamten): Approved 19-Dec-2025 for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Includes a Boxed Warning for heart failure risk. Cytokinetics, Inc. FDA Link

  • Fesilty (fibrinogen, human-chmt): Approved 19-Dec-2025 for acute bleeding in patients with congenital fibrinogen deficiency. Octapharma. FDA Link

  • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj): Subcutaneous formulation approved 18-Dec-2025 for EGFR-mutated non-small cell lung cancer (NSCLC). Johnson & Johnson. FDA Link

  • Exdensur (depemokimab-ulaa): Approved 16-Dec-2025 as the first ultra-long-acting IL-5 antagonist for severe eosinophilic asthma (administered twice yearly). GSK. FDA Link

  • Nuzolvence (zoliflodacin): Approved 12-Dec-2025 for uncomplicated urogenital gonorrhea. First-in-class oral antibiotic for MDR strains. Innoviva. FDA Link

  • Lerochol (lerodalcibep-liga): Approved 12-Dec-2025 to reduce LDL-C in adults with hypercholesterolemia. LIB Therapeutics. FDA Link

  • Uplizna (inebilizumab-cdon): Label expansion approved 11-Dec-2025 for generalized Myasthenia Gravis (gMG) in AChR+ and MuSK+ patients. Amgen. FDA Link

  • Waskyra (etuvetidigene autotemcel): Approved 09-Dec-2025 as the first gene therapy for Wiskott-Aldrich Syndrome. Rocket Pharmaceuticals. FDA Link

  • Breyanzi (lisocabtagene maraleucel): Approved 04-Dec-2025 as the first CAR T-cell therapy for relapsed/refractory marginal zone lymphoma (MZL). Bristol Myers Squibb. FDA Link

M&A Deals

  • Pfizer acquires Metsera: $10 billion (Closed Dec 2025). Pfizer beat out Novo Nordisk in a bidding war to secure Metsera’s GLP-1/GIP obesity pipeline. Source

  • Merck acquires Cidara Therapeutics: $9.2 billion (Announced Dec 2025). Focus on CD388, a universal long-acting antiviral for influenza prevention. Source

  • Thermo Fisher acquires Clario: $9.4 billion (Announced Dec 2025). Strategic move to integrate high-end clinical-trial endpoint data and analytics. Source

  • J&J acquires Intra-Cellular Therapies: $14.6 billion (Completed). The largest biopharma deal of the year, securing Caplyta for neuropsychiatric indications. Source

  • Novartis acquires Avidity Biosciences: $12 billion (Closed Dec 2025). Expands Novartis’ reach into RNA-based therapies for rare neuromuscular diseases. Source

Clinical Trial Setbacks

  • Sanofi (tolebrutinib): Discontinued development for Primary Progressive Multiple Sclerosis (PPMS) after Phase 3 PERSEUS trial failed to meet the primary endpoint of delaying disability progression (Dec 15, 2025). Source

  • Kamada Pharmaceuticals: Terminated Phase 3 trial for Inhaled AAT (Alpha-1 Antitrypsin) in December following a futility analysis. Source

  • NIH Funding Freeze: In Dec 2025, federal budget constraints led to a pause in roughly 3.5% of all NIH-funded active trials, affecting approximately 74,000 enrolled patients. Source

Technological Breakthroughs

  • FDA Qualifies First AI Drug Development Tool (DDT): On Dec 8, 2025, the FDA officially qualified an AI-driven tool for patient stratification in MASH (formerly NASH) trials, marking a regulatory milestone for generative AI in trial design. Source

  • Edge AI for Patient Monitoring: New data from Jan 2026 suggests "Edge AI" wearables (processing data on-device) reduced data latency in decentralized trials by 40%, significantly improving remote patient safety monitoring. Source

Market Insights

  • The 2026 "Patent Cliff": Major expiries for blockbusters like Keytruda and Darzalex are projected to trigger a $230 billion revenue loss by 2030, fueling the current surge in aggressive, late-stage M&A. Source

  • Oncology Shift: While oncology still leads M&A volume, deal values in Neuroscience and Metabolic (Obesity/MASH) diseases have surpassed oncology for the first time in five years as of Q4 2025. Source

Summary Table: Recent Major FDA Actions

Brand NameActive IngredientCompanyIndicationApproval Date
NereusTradipitantVandaMotion Sickness (Vomiting)30-Dec-2025
YartemleaNarsoplimabOmerosHSCT-TMA24-Dec-2025
AqvesmeMitapivatAgiosThalassemia Anemia23-Dec-2025
MyqorzoAficamtenCytokineticsObstructive HCM19-Dec-2025
ExdensurDepemokimabGSKSevere Eosinophilic Asthma16-Dec-2025
NuzolvenceZoliflodacinInnovivaGonorrhea12-Dec-2025
LerocholLerodalcibepLIB TherapeuticsHypercholesterolemia12-Dec-2025
WaskyraEtuvetidigeneRocket PharmaWiskott-Aldrich Syndrome09-Dec-2025
BreyanziLiso-celBMSMarginal Zone Lymphoma04-Dec-2025
- No comments:
Subscribe to: Posts (Atom)